Spirometer Calibration Syringe: Market Size
Based on available data, the U.S. market size for Spirometer Calibration Syringes is $8,469,336,750. There are approximately 249,465 locations that require a Spirometer Calibration Syringe to keep the coinciding equipment functioning properly.
- There are 5 segments of health care providers that use Spirometers:
- Hospitals within the U. S = 6,146
- Pulmonologists within the U.S. =3,419
- General Medical Practitioners within the U.S. = 209,000
- Retail Clinics and Emergent Facilities within the U.S. = 2,000
- Assisted Living Facilities within the U.S. = 28,900
- Spirometers are devices which treat COPD caused by multiple lung diseases. Spirometer Calibration Syringes are necessary to calibrate the Spirometer medical device used by Pulmonologists, general practitioners, assisted living facilities, hospitals, and retail clinics.
- The established statistic of patients with COPD in the U.S. is estimated to be 24 million. Calibration is recommended after each use.
- However, if it is a high traffic medical facility, it can be calibrated after 10 patients. Spirometer Calibration Syringes usually cost $350, with a 1-year warranty for replacements at no cost within that first year. This medical equipment is usually a lifetime product, however it will need to be replaced if damaged, dropped accidentally, lost, or overused.
US MARKET SIZE
- Based on the data available, the amount of use can not determine how often the damage occurs. However, from the information available, it can be extrapolated that the Spirometer Calibration Syringe should be replaced yearly.
- If there are 249,465 locations, and there are approximately 24 million patients, it is safe to assume that there are roughly 97 patients per location.
- If the average cost of a Spirometer Calibration Syringe is $350 and one location has roughly 97 patients in need of this device, the annual cost would be $33,950.
- That would conclude that the annual market size for Spirometer Calibration Syringes would come to $8,469,336,750, assuming the number of U.S. patients remain the same.